

Amendments to the Claims

1. (Original) An antibody that recognizes a tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL receptor).
2. (Original) The antibody of claim 1, which is a minibody.
3. (Currently Amended) The antibody of claim 1 ~~or 2~~, which comprises three or more antigen binding sites.
4. (Original) The antibody of claim 3, which comprises three antigen binding sites.
5. (Original) The antibody of claim 4, wherein three scFv units form a trimer.
6. (Original) The antibody of claim 5, wherein two of the variable regions in the scFv units are linked together *via* a linker with zero to two amino acids.
7. (Original) The antibody of claim 6, wherein the linker comprises zero amino acids.
8. (Original) The antibody of claim 6, wherein the linker comprises one amino acid.
9. (Original) The antibody of claim 3, which comprises four antigen binding sites.
10. (Original) The antibody of claim 9, wherein a polypeptide comprising four variable regions forms a dimer.
11. (Currently Amended) The antibody of claim 1 ~~any one of claims 1 to 10~~, wherein the TRAIL receptor is TRAIL-R1 or TRAIL-R2.
12. (Currently Amended) The antibody of claim 1 ~~any one of claims 1 to 11~~, which induces apoptosis in a cell.
13. (Original) The antibody of claim 12, wherein the cell is a tumor cell.
14. (Currently Amended) An antibody comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, or 8.
15. – 17. (Canceled)
18. (Original) An antibody that comprises three or more antigen binding sites and induces apoptosis in a cell.
19. (Original) The antibody of claim 18, which comprises three antigen binding sites.
20. (Original) The antibody of claim 18, which comprises four antigen binding sites.
21. (Currently Amended) The antibody of claim 18 ~~any one of claims 18 to 20~~, wherein the cell is a tumor cell.

22. (Currently Amended) An isolated polynucleotide encoding the antibody of claim 1~~any one of claims 1 to 21~~.

23. (Currently Amended) An isolated polynucleotide that hybridizes under stringent conditions to a the polynucleotide that encodes the antibody of claim 1~~of claim 22 under stringent conditions~~ and encodes an antibody with an activity equivalent to that of the antibody of claim 1~~any one of claims 1 to 21~~.

24. (Currently Amended) A vector carrying the polynucleotide of claim 22 ~~or 23~~.

25. (Currently Amended) A host cell carrying the polynucleotide of claim 22 ~~or 23~~, ~~or the vector of claim 24~~.

26. (Currently Amended) A pharmaceutical composition comprising the antibody of claim 1~~any one of claims 1 to 21~~.